FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, to a method for selective destruction of prostate gland enlargement. Method involves administering fexapotide triflutate to a human patient with benign prostatic hyperplasia (BPH) as an multiple-dose infusion in more than two to 10 different areas of the prostate gland and more than once at different times after initial administration, for treating more than 95% of the prostate gland, with a total dosage in the range of 20 to 350 mg.
EFFECT: invention is effective for selective destruction of prostate gland enlargement, preserving the nerves, stromal, vascular, and connective tissues, as well as the urethral muscles.
13 cl, 1 dwg, 4 tbl, 1 ex
